Invacare is a clinical-stage biopharmaceutical company with no approved products and no commercial revenue, focused entirely on developing INZ-701, a recombinant fusion protein designed to treat rare diseases caused by dysfunction in the PPi-Adenosine Pathway. INZ-701 mimics the human ENPP1 enzyme, which normally produces PPi and adenosine — molecules that prevent calcium from depositing in soft tissues and blood vessels and stop smooth muscle cells from overgrowing inside blood vessels. In patients with ENPP1 Deficiency, the absence of these molecules causes severe calcification and vascular narrowing, a disease that kills roughly half of affected infants within six months of birth and has no approved treatments. INZ-701 is administered via weekly subcutaneous injection and is designed as a chronic, lifelong therapy. The lead program is a pivotal pediatric trial (ENERGY 3) with topline data expected in Q1 2026 and a potential BLA filing and commercial launch targeted for the first half of 2027. INZ-701 is also being studied in ABCC6 Deficiency and calciphylaxis, though those programs are deferred pending the ENPP1 BLA. If approved, Invacare plans to commercialize INZ-701 directly through a small, targeted sales force aimed at specialist physicians at rare disease centers, with premium pricing consistent with standard rare disease strategy. INZ-701 holds orphan drug designation from both the FDA and EMA, providing up to seven years of U.S. and ten years of EU marketing exclusivity. Operations are funded through equity issuances and debt, with spending concentrated on clinical trials and contract manufacturing.